240 related articles for article (PubMed ID: 8375017)
1. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
Denny WA; Wilson WR
Cancer Metastasis Rev; 1993 Jun; 12(2):135-51. PubMed ID: 8375017
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards.
Ware DC; Palmer BD; Wilson WR; Denny WA
J Med Chem; 1993 Jun; 36(13):1839-46. PubMed ID: 8515422
[TBL] [Abstract][Full Text] [Related]
3. Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins capable of releasing diffusible cytotoxins on bioreduction.
Denny WA; Wilson WR; Tercel M; Van Zijl P; Pullen SM
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):317-21. PubMed ID: 8195026
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumors with hypoxia-activated cytotoxins.
Ahn GO; Brown M
Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
[TBL] [Abstract][Full Text] [Related]
5. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
Patterson LH
Cancer Metastasis Rev; 1993 Jun; 12(2):119-34. PubMed ID: 8375016
[TBL] [Abstract][Full Text] [Related]
6. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
Hay MP; Denny WA; Wilson WR
Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines.
Palmer BD; Wilson WR; Pullen SM; Denny WA
J Med Chem; 1990 Jan; 33(1):112-21. PubMed ID: 2296009
[TBL] [Abstract][Full Text] [Related]
8. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771.
Wilson WR; Moselen JW; Cliffe S; Denny WA; Ware DC
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):323-7. PubMed ID: 8195027
[TBL] [Abstract][Full Text] [Related]
9. A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs.
Parker LL; Lacy SM; Farrugia LJ; Evans C; Robins DJ; O'Hare CC; Hartley JA; Jaffar M; Stratford IJ
J Med Chem; 2004 Nov; 47(23):5683-9. PubMed ID: 15509167
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing.
Wilson WR; Pruijn FB
Clin Exp Pharmacol Physiol; 1995 Nov; 22(11):881-5. PubMed ID: 8593750
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
Tercel M; Lee AE; Hogg A; Anderson RF; Lee HH; Siim BG; Denny WA; Wilson WR
J Med Chem; 2001 Oct; 44(21):3511-22. PubMed ID: 11585455
[TBL] [Abstract][Full Text] [Related]
12. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
Wilson WR; Tercel M; Anderson RF; Denny WA
Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
[TBL] [Abstract][Full Text] [Related]
13. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
14. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
15. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
16. Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins.
Ware DC; Palmer HR; Pruijn FB; Anderson RF; Brothers PJ; Denny WA; Wilson WR
Anticancer Drug Des; 1998 Mar; 13(2):81-103. PubMed ID: 9524553
[TBL] [Abstract][Full Text] [Related]
17. Nitro reduction as an electronic switch for bioreductive drug activation.
Siim BG; Denny WA; Wilson WR
Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
Denny WA
Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
[TBL] [Abstract][Full Text] [Related]
19. Bis-tropolonato derivatives of cobalt(III) complexes of bidentate aliphatic nitrogen mustards as potential hypoxia-selective cytotoxins.
Ware DC; Palmer HR; Brothers PJ; Rickard CE; Wilson WR; Denny WA
J Inorg Biochem; 1997 Nov; 68(3):215-24. PubMed ID: 9352654
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
Henderson ND; Plumb JA; Robins DJ; Workman P
Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
